1-3 of 3
Navin R. Pinto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Manali K. Kamdar, Bradley M. Haverkos, Alexander W. Rankin, Cheri Adams, Michael R Verneris, Andrew Roth, Kimberly Jordan, Navin R. Pinto, M. Eric Kohler, Angela Ohm, Terry J Fry
Journal: Blood
Blood (2024) 144 (Supplement 1): 4510.
https://doi.org/10.1182/blood-2024-210123
Published: 2024
Journal Articles

Use of CD19 CAR-T Cells in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Minimal Residual Disease (MRD) Positivity at First Complete Remission: Preliminary Outcomes from a Phase I Clinical Trial

Marc Schwartz, Navin R. Pinto, Jonathan Gutman, Michael R Verneris, Andrew Roth, Jason S. Gilbert, Dina Schneider, Terry J Fry
Journal: Blood
Blood (2024) 144 (Supplement 1): 5876.
https://doi.org/10.1182/blood-2024-204262
Published: 2024
Journal Articles

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Rebecca Gardner, MD, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Julie Rivers, MD, Juliane Gust, MD, Katherine Tarlock, MD, Todd M Cooper, DO, Navin R. Pinto, MD, Olivia Finney, PhD, Hannah Smithers, MS, Assaf Oron, PhD, Daniel Li, PhD, Julie R Park, MD, Michael C Jensen, MD
Journal: Blood
Blood (2016) 128 (22): 586.
https://doi.org/10.1182/blood.V128.22.586.586
Published: 2016